These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 21380937)

  • 1. Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn's disease: a randomized placebo-controlled trial.
    Smith JP; Bingaman SI; Ruggiero F; Mauger DT; Mukherjee A; McGovern CO; Zagon IS
    Dig Dis Sci; 2011 Jul; 56(7):2088-97. PubMed ID: 21380937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low dose naltrexone for induction of remission in Crohn's disease.
    Segal D; Macdonald JK; Chande N
    Cochrane Database Syst Rev; 2014 Feb; (2):CD010410. PubMed ID: 24558033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low dose naltrexone for induction of remission in Crohn's disease.
    Parker CE; Nguyen TM; Segal D; MacDonald JK; Chande N
    Cochrane Database Syst Rev; 2018 Apr; 4(4):CD010410. PubMed ID: 29607497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and tolerability of low-dose naltrexone therapy in children with moderate to severe Crohn's disease: a pilot study.
    Smith JP; Field D; Bingaman SI; Evans R; Mauger DT
    J Clin Gastroenterol; 2013 Apr; 47(4):339-45. PubMed ID: 23188075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study.
    Feagan BG; Sandborn WJ; D'Haens G; Panés J; Kaser A; Ferrante M; Louis E; Franchimont D; Dewit O; Seidler U; Kim KJ; Neurath MF; Schreiber S; Scholl P; Pamulapati C; Lalovic B; Visvanathan S; Padula SJ; Herichova I; Soaita A; Hall DB; Böcher WO
    Lancet; 2017 Apr; 389(10080):1699-1709. PubMed ID: 28411872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-dose naltrexone therapy improves active Crohn's disease.
    Smith JP; Stock H; Bingaman S; Mauger D; Rogosnitzky M; Zagon IS
    Am J Gastroenterol; 2007 Apr; 102(4):820-8. PubMed ID: 17222320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Accuracy of magnetic resonance enterography in assessing response to therapy and mucosal healing in patients with Crohn's disease.
    Ordás I; Rimola J; Rodríguez S; Paredes JM; Martínez-Pérez MJ; Blanc E; Arévalo JA; Aduna M; Andreu M; Radosevic A; Ramírez-Morros AM; Pinó S; Gallego M; Jauregui-Amezaga A; Ricart E; Panés J
    Gastroenterology; 2014 Feb; 146(2):374-82.e1. PubMed ID: 24177375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC.
    Ferrante M; Colombel JF; Sandborn WJ; Reinisch W; Mantzaris GJ; Kornbluth A; Rachmilewitz D; Lichtiger S; D'Haens GR; van der Woude CJ; Danese S; Diamond RH; Oortwijn AF; Tang KL; Miller M; Cornillie F; Rutgeerts PJ;
    Gastroenterology; 2013 Nov; 145(5):978-986.e5. PubMed ID: 23954314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of therapeutic effect of low dose naltrexone in experimentally-induced Crohn's disease in rats.
    Tawfik DI; Osman AS; Tolba HM; Khattab A; Abdel-Salam LO; Kamel MM
    Neuropeptides; 2016 Oct; 59():39-45. PubMed ID: 27392602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial.
    Colombel JF; Panaccione R; Bossuyt P; Lukas M; Baert F; Vaňásek T; Danalioglu A; Novacek G; Armuzzi A; Hébuterne X; Travis S; Danese S; Reinisch W; Sandborn WJ; Rutgeerts P; Hommes D; Schreiber S; Neimark E; Huang B; Zhou Q; Mendez P; Petersson J; Wallace K; Robinson AM; Thakkar RB; D'Haens G
    Lancet; 2017 Dec; 390(10114):2779-2789. PubMed ID: 29096949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Azathioprine is superior to budesonide in achieving and maintaining mucosal healing and histologic remission in steroid-dependent Crohn's disease.
    Mantzaris GJ; Christidou A; Sfakianakis M; Roussos A; Koilakou S; Petraki K; Polyzou P
    Inflamm Bowel Dis; 2009 Mar; 15(3):375-82. PubMed ID: 19009634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study.
    Feagan BG; Panés J; Ferrante M; Kaser A; D'Haens GR; Sandborn WJ; Louis E; Neurath MF; Franchimont D; Dewit O; Seidler U; Kim KJ; Selinger C; Padula SJ; Herichova I; Robinson AM; Wallace K; Zhao J; Minocha M; Othman AA; Soaita A; Visvanathan S; Hall DB; Böcher WO
    Lancet Gastroenterol Hepatol; 2018 Oct; 3(10):671-680. PubMed ID: 30056030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eldelumab [anti-interferon-γ-inducible protein-10 antibody] Induction Therapy for Active Crohn's Disease: a Randomised, Double-blind, Placebo-controlled Phase IIa Study.
    Sandborn WJ; Rutgeerts P; Colombel JF; Ghosh S; Petryka R; Sands BE; Mitra P; Luo A
    J Crohns Colitis; 2017 Jul; 11(7):811-819. PubMed ID: 28333187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol.
    Hébuterne X; Lémann M; Bouhnik Y; Dewit O; Dupas JL; Mross M; D'Haens G; Mitchev K; Ernault É; Vermeire S; Brixi-Benmansour H; Moreels TG; Mary JY; Marteau P; Colombel JF
    Gut; 2013 Feb; 62(2):201-8. PubMed ID: 22525883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endoscopic and histologic evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn's disease.
    Geboes K; Rutgeerts P; Opdenakker G; Olson A; Patel K; Wagner CL; Marano CW
    Curr Med Res Opin; 2005 Nov; 21(11):1741-54. PubMed ID: 16307694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and Efficacy of an Oral Inhibitor of the Purinergic Receptor P2X7 in Adult Patients with Moderately to Severely Active Crohn's Disease: A Randomized Placebo-controlled, Double-blind, Phase IIa Study.
    Eser A; Colombel JF; Rutgeerts P; Vermeire S; Vogelsang H; Braddock M; Persson T; Reinisch W
    Inflamm Bowel Dis; 2015 Oct; 21(10):2247-53. PubMed ID: 26197451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial.
    Vermeire S; Schreiber S; Petryka R; Kuehbacher T; Hebuterne X; Roblin X; Klopocka M; Goldis A; Wisniewska-Jarosinska M; Baranovsky A; Sike R; Stoyanova K; Tasset C; Van der Aa A; Harrison P
    Lancet; 2017 Jan; 389(10066):266-275. PubMed ID: 27988142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endoscopic, Radiologic, and Histologic Healing With Vedolizumab in Patients With Active Crohn's Disease.
    Danese S; Sandborn WJ; Colombel JF; Vermeire S; Glover SC; Rimola J; Siegelman J; Jones S; Bornstein JD; Feagan BG
    Gastroenterology; 2019 Oct; 157(4):1007-1018.e7. PubMed ID: 31279871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's Disease.
    Sandborn WJ; Feagan BG; Loftus EV; Peyrin-Biroulet L; Van Assche G; D'Haens G; Schreiber S; Colombel JF; Lewis JD; Ghosh S; Armuzzi A; Scherl E; Herfarth H; Vitale L; Mohamed MF; Othman AA; Zhou Q; Huang B; Thakkar RB; Pangan AL; Lacerda AP; Panes J
    Gastroenterology; 2020 Jun; 158(8):2123-2138.e8. PubMed ID: 32044319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ozanimod induction therapy for patients with moderate to severe Crohn's disease: a single-arm, phase 2, prospective observer-blinded endpoint study.
    Feagan BG; Sandborn WJ; Danese S; Wolf DC; Liu WJ; Hua SY; Minton N; Olson A; D'Haens G
    Lancet Gastroenterol Hepatol; 2020 Sep; 5(9):819-828. PubMed ID: 32553149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.